Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | BHB810 |
| Synonyms | |
| Therapy Description |
BHB810 is an antibody-drug conjugate (ADC) comprising a monoclonal antibody targeting CDH17 linked to MMAE, which potentially inhibits growth of CDH17-expressing tumors (Cancer Res (2026) 86 (7_Supplement): 6922). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| BHB810 | BHB-810|BHB 810 | BHB810 is an antibody-drug conjugate (ADC) comprising a monoclonal antibody targeting CDH17 linked to MMAE, which potentially inhibits growth of CDH17-expressing tumors (Cancer Res (2026) 86 (7_Supplement): 6922). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07529808 | Phase Ib/II | BHB810 | Phase 1/2 Study of BHB810 in Advanced Gastric and GEJ Adenocarcinoma | Recruiting | USA | 0 |